Lung Cancer Community Applauds Latest Research Confirming Life-Saving, Low-Cost Benefits of Lung Cancer Early Detection in High-Risk Population

Posted by Samantha Powell on September 2nd, 2014 |

The American College of Radiology (ACR), Lung Cancer Alliance (LCA), Medical Imaging & Technology Alliance (MITA) and The Society of Thoracic Surgeons (STS) today applauded an actuarial cost-benefit analysis conducted by Milliman, Inc. that found implementation of the U.S. Preventive Services Task Force (USPSTF) recommendations for low-dose computed tomography (LDCT) for the early detection of lung cancer in high-risk Medicare beneficiaries is highly cost effective.

The study, published in the August issue of American Health and Drug Benefits, determined that 4.9 million Medicare beneficiaries aged 55-80 years would be eligible for screening in 2014. It found that the life-saving value of this service is a good financial investment. In fact, actuaries estimated that LDCT plus follow-up diagnostics would cost approximately $1 per insured member per month (PMPM) and the cost per life-year saved would be less than $19,000. The cost per life-year saved is lower than screening for cervical and breast cancers and comparable to colorectal cancer screening. Researchers also commented that LDCT fits well within the standard Medicare program, including its claims payment and quality monitoring.

“This analysis completes the enormous body of evidence which demonstrates that lung cancer screening of high-risk Medicare beneficiaries is not only life-saving but more cost-effective than other cancer screening protocols currently covered by Medicare,” said Laurie Fenton Ambrose, president & CEO of LCA. “We saw very similar life-saving, cost-effectiveness results with previous studies on screening the at-risk under 65 population, which some commercial insurers started covering as a benefit in 2011, and which all will be required to do, with few exceptions, over the coming year.”

The latest Milliman analysis echoes an actuarial analysis published in Health Affairs in 2012 that found LDCT lung cancer screening for the high-risk commercially-insured population is cost effective.

A co-author of both studies, Bruce Pyenson, FSA, MAAA, Principal & Consulting Actuary, Milliman, Inc. said, “The evidence continues to show that implementing comprehensive lung cancer screening programs for high-risk individuals would cure many lung cancers each year and also add years to thousands of people’s lifetimes at a relatively low cost.”

Lung cancer is the leading cause of cancer deaths in Medicare. In the United States, more people die of lung cancer each year than colon, breast, pancreas and prostate cancers combined. LDCT scans allow lung cancer to be detected when the disease is in its earliest, most curable stages.

“The research underscores what we already know from practice — that we can save lives in a cost effective manner with LDCT scans,” said Ella Kazerooni, MD, chair of the ACR Committee on Lung Cancer Screening. “Medicare coverage would be a monumental step in the expansion of access to this invaluable tool for the early detection of lung cancer.”

Date: 9/2/14
Outlet Full Name: Insurance News Net
Author: Linda Koco–a-550870.html#.VAdQZcKwKf8

Comments are closed.